What question did this study set out to answer?

The aim is to evaluate the safety and efficacy of a combination therapy for muscle-invasive bladder cancer.

March 4, 2026Journal of Clinical Oncology0 citations

Liquid biopsy guided disitamab vedotin combined with toripalimab and radiotherapy for multimodal organ-sparing treatment of muscle invasive bladder cancer (DECIDING-I study).

RZRuiyun ZhangShanghai Jiao Tong University DJD. JinShanghai Jiao Tong University LQLei QianShanghai Jiao Tong University

Puntos clave

The aim is to evaluate the safety and efficacy of a combination therapy for muscle-invasive bladder cancer.
Assessed disitamab vedotin with toripalimab and radiotherapy in a proof-of-concept study.
Conducted longitudinal liquid biopsy analyses using the PredicineCARE assay.
Monitored circulating tumor DNA and urinary tumor DNA to evaluate treatment response and relapse.
Combination therapy showed a favorable safety profile with no severe side effects.
83.3% of patients achieved a complete response and remained recurrence-free during follow-up.
Urinary tumor DNA proved effective in tracking therapy success and detecting early recurrences.

Resumen

849 Background: Trimodal therapy remains the standard organ-sparing approach for muscle-invasive bladder cancer (MIBC), yet its clinical benefits are limited, and noninvasive biomarkers to guide dynamic treatment decisions are currently unavailable. There is an urgent need for innovative therapeutic strategies and reliable biomarkers to improve outcomes in localized HER2-positive MIBC. Methods: In this proof-of-concept study, we evaluated the safety and efficacy of disitamab vedotin (RC48, a HER2-targeted antibody-drug conjugate) combined with toripalimab (JS001, anti-PD-1) and radiotherapy in six patients with localized HER2-positive MIBC (DECIDING-1 study, ClinicalTrials.gov: NCT05979740). Longitudinal liquid biopsy analyses were performed using the PredicineCARE assay to profile circulating tumor DNA (ctDNA) and urinary tumor DNA (utDNA), assessing their utility in monitoring treatment response and detecting relapse. Results: The combination therapy demonstrated a favorable safety profile, with no grade 4 treatment-related adverse events or deaths observed. Five patients (83.3%) achieved a complete response and remained recurrence-free during follow-up. Longitudinal biomarker analysis revealed that utDNA testing exhibited high accuracy in tracking therapeutic efficacy and enabled early detection of tumor recurrence, whereas ctDNA was largely undetectable in blood samples. Conclusions: This study establishes the feasibility and efficacy of a novel bladder-preserving regimen combining HER2-targeted therapy, immunotherapy, and radiotherapy for HER2-positive MIBC. DECIDING-II is recruiting for validation in a larger cohort. Furthermore, utDNA emerges as a promising noninvasive biomarker for real-time monitoring and early relapse detection. These findings support further investigation of this approach as a potential paradigm shift in MIBC management. Clinical trial information: NCT05979740 .

Preguntar a la IA

Me gusta

Guardar

Ver artículo completo